Gibco KnockOut Media

Feeder-dependent culture proven more reliable than FBS

Gibco KnockOut reagents represent some of the most cited products for culturing human and mouse pluripotent stem cells (PSCs). With over 4,000 peer-reviewed publications covering applications such as PSC culture, differentiation, iPSC generation, and ESC derivation, KnockOut products are trusted for feeder-dependent PSC culture.

Need help?   View resources


Choose the Gibco KnockOut products that best fit your stem cell culture needs.

ApplicationProductBenefits
Feeder-dependent: Research use onlyKnockOut Serum Replacement (KSR)
  • A defined substitute for serum, meant for the culture of ESCs and iPSCs
  • Cited in over 2,000 publications for various PSC-related applications
  • Helps to reduce the burden of qualifying reagents when transitioning to clinical applications
Xeno-free and feeder-dependent: Clinical applicationsCTS KnockOut SR XenoFree Medium
  • A xeno-free formulation that supports the derivation and maintenance of human ESCs and iPSCs
  • Maintains normal morphology, karyotype, and pluripotency gene expression
  • Helps to reduce the burden of qualifying reagents when transitioning to clinical applications

Choose the Gibco KnockOut basal medium that best fits your stem cell culture needs

ApplicationProductBenefits
Feeder-dependent PSC cultureKnockOut DMEM
  • A chemically defined basal medium designed for ESCs and iPSCs
  • Mimics the low-osmolality environment of mouse embryonic tissues
  • Reduces PSC differentiation, especially when used with KnockOut SR – Multi-Species
Feeder-dependent PSC culture:
Clinical applications
CTS KnockOut DMEM
  • A chemically defined, low-osmolality basal medium for ESCs and iPSCs
  • Helps to reduce the burden of qualifying reagents when transitioning to clinical applications
Neural stem cell cultureKnockOut DMEM/F-12
  • A chemically defined, low-osmolality basal medium without HEPES buffer
  • Supports expansion and differentiation of neural stem cells
  • Maintains human ESCs and iPSCs with normal morphology and karyotype
Neural stem cell culture: Clinical applicationsCTS KnockOut DMEM/F-12
  • A chemically defined, low-osmolality basal medium for neural stem cells or ESCs and iPSCs
  • Helps to reduce the burden of qualifying reagents when transitioning to clinical applications
ApplicationProductBenefits
Feeder-dependent: Research use onlyKnockOut Serum Replacement (KSR)
  • A defined substitute for serum, meant for the culture of ESCs and iPSCs
  • Cited in over 2,000 publications for various PSC-related applications
  • Helps to reduce the burden of qualifying reagents when transitioning to clinical applications
Xeno-free and feeder-dependent: Clinical applicationsCTS KnockOut SR XenoFree Medium
  • A xeno-free formulation that supports the derivation and maintenance of human ESCs and iPSCs
  • Maintains normal morphology, karyotype, and pluripotency gene expression
  • Helps to reduce the burden of qualifying reagents when transitioning to clinical applications

Choose the Gibco KnockOut basal medium that best fits your stem cell culture needs

ApplicationProductBenefits
Feeder-dependent PSC cultureKnockOut DMEM
  • A chemically defined basal medium designed for ESCs and iPSCs
  • Mimics the low-osmolality environment of mouse embryonic tissues
  • Reduces PSC differentiation, especially when used with KnockOut SR – Multi-Species
Feeder-dependent PSC culture:
Clinical applications
CTS KnockOut DMEM
  • A chemically defined, low-osmolality basal medium for ESCs and iPSCs
  • Helps to reduce the burden of qualifying reagents when transitioning to clinical applications
Neural stem cell cultureKnockOut DMEM/F-12
  • A chemically defined, low-osmolality basal medium without HEPES buffer
  • Supports expansion and differentiation of neural stem cells
  • Maintains human ESCs and iPSCs with normal morphology and karyotype
Neural stem cell culture: Clinical applicationsCTS KnockOut DMEM/F-12
  • A chemically defined, low-osmolality basal medium for neural stem cells or ESCs and iPSCs
  • Helps to reduce the burden of qualifying reagents when transitioning to clinical applications